Citigroup Inc. increased its stake in Mettler-Toledo International, Inc. (NYSE:MTD) by 137.7%, owning 30,891 shares worth approximately $36.48 million following the purchase of an additional 17,893 shares during the first quarter. The institutional investor owned 0.15% of Mettler-Toledo International worth $36,479,000 at the end of the most recent reporting period. Several other hedge funds and institutional investors also boosted their holdings in the company. Farther Finance Advisors LLC grew its position by 39.1%, now owning 89 shares worth $103,000 after acquiring 25 additional shares. QRG Capital Management Inc. increased its stake by 29.4%, now holding 489 shares worth $577,000 after purchasing 111 shares. Mirae Asset Global Investments Co. Ltd. boosted its holdings by 13.3%, now owning 2,488 shares worth $2,929,000 after acquiring 292 shares. Wealth Enhancement Advisory Services LLC increased its stake by 95.0%, now owning 2,202 shares valued at $2,600,000 after purchasing 1,073 shares. Boston Trust Walden Corp raised its holdings by 7.1%, now owning 34,610 shares worth $40,871,000 after purchasing 2,296 shares. Together, 95.07% of the stock is owned by institutional investors.\n\nIn addition, a director sold 1,062 shares of Mettler-Toledo International at an average price of $1,159.93, for a total value of $1,231,845.66, reducing their ownership to 120 shares valued at $139,191.60, representing an 89.85% decrease in ownership. This transaction was disclosed in a filing with the SEC.\n\nMettler-Toledo International shares opened at $1,258.27 on Tuesday. The stock has a 1-year low of $946.69 and a 1-year high of $1,521.01. The company has a market capitalization of $25.92 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 3.77, and a beta of 1.34. The fifty-day moving average is $1,204.46 and the two-hundred-day moving average is $1,189.31.\n\nThe company reported a quarterly earnings per share of $10.09, exceeding analysts' expectations of $9.58, with revenue of $983.22 million, up 3.9% year-over-year. The net margin was 21.46%, and the return on equity was negative at -476.07%. For the current fiscal year, equities research analysts predict earnings per share of $42.71.\n\nAnalyst ratings and price targets include: Evercore ISI lowered its price target from $1,280.00 to $1,275.00 and maintained an 'outperform' rating; Barclays set an 'overweight' rating and a $1,325.00 target price; UBS Group upgraded to a 'buy' rating and cut the target to $1,350.00; Jefferies Financial Group upgraded to a 'hold' rating and lowered the target to $1,110.00. Six analysts have a 'hold' rating and five have a 'buy' rating, resulting in a consensus rating of 'Hold' and an average price target of $1,288.89.\n\nMettler-Toledo International manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. Its laboratory instruments include balances, pipetting solutions, automated reactors, real-time analytics, titrators, pH meters, process sensors, and other analytical instruments. It also offers LabX, a laboratory software platform for managing and analyzing data generated from its instruments.

Mettler-Toledo International, Inc. (NYSE:MTD) Shares Acquired by Citigroup Inc.

Citigroup Inc. increased its stake in Mettler-Toledo International, Inc. by 137.7%, owning 30,891 shares valued at approximately $36.48 million. Other institutional investors, including Farther Finance Advisors LLC, QRG Capital Management Inc., Mirae Asset Global Investments Co. Ltd., Wealth Enhancement Advisory Services LLC, and Boston Trust Walden Corp, also expanded their holdings. A director sold 1,062 shares worth $1.23 million, reducing their ownership significantly. Mettler-Toledo reported strong quarterly earnings per share of $10.09, exceeding expectations, with revenue of $983.22 million and a net margin of 21.46%. The company has a market capitalization of $25.92 billion and operates globally in precision instrumentation and laboratory services. Analysts have adjusted price targets, with UBS upgrading to a 'buy' and lowering the target to $1,350.00, while consensus rating remains 'Hold' at $1,288.89.